ArticleInterdisciplinary cardiovascular and thoracic surgery2026
Resectability and Neoadjuvant Chemoimmunotherapy in Stage II-III Non-Small Cell Lung Cancer: A European Case-Vignette Survey.
Article in Interdisciplinary cardiovascular and thoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesImmunotherapy has expanded curative-intent options in non-small cell lung cancer (NSCLC), but management recommendations remain variable. This survey examined variation in resectability assessment and treatment sequencing among thoracic oncology clinicians managing stage II-III NSCLC.
methodsA web-based case-vignette survey was distributed to thoracic oncology clinicians, primarily in Europe. Seven stage II-III NSCLC vignettes, based on the ninth-edition TNM classification, were presented. Treatment options were recorded as independent yes/no endorsements. The primary outcome was endorsement of neoadjuvant chemoimmunotherapy among vignette evaluations considered resectable. Vignette-level binary outcomes were analysed using exploratory generalized estimating equations clustered by respondent.
resultsSixty-eight respondents provided vignette-level assessments. Resectability was generally endorsed in the N0/N1 and selected single-station N2 scenarios but was substantially lower in the multi-station and T3/T4 N2 scenarios. Among cases considered resectable, endorsement of neoadjuvant chemoimmunotherapy increased markedly in N2 scenarios, whereas cases considered unresectable were commonly associated with endorsement of concurrent chemoradiotherapy. In an exploratory model restricted to resectable-branch evaluations (249 observations from 57 respondents), any N2 involvement was associated with endorsement of neoadjuvant chemoimmunotherapy (adjusted odds ratio 28.42, 95% CI 7.31-110.42; P < .001), though the wide interval reflects the limited effective sample.
conclusionsVariation was greatest in borderline N2 disease, particularly multi-station and higher-T N2 scenarios, where clinicians diverged in defining resectability and in selecting surgery-based vs chemoradiotherapy-based pathways. These findings support the need for clearer multidisciplinary frameworks in stage II-III NSCLC, within the limits of a surgeon-weighted respondent pool and an anatomically focused vignette set.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.